Dear EURETINA Members, A very warm welcome to the April 28th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »April 28th, 2025 “EURETINA-Brief”© Issue No. 315
Clinical researchers at the Department of Ophthalmology and Johnson Retina Centre, University of Washington, Seattle, have reported on the clinical characteristics, natural history, genetic landscape,… Read More »Research provides new insight into how individual genotypes can influence phenotypic features in neuronal ceroid lipofuscinosis (NCL)-associated retinal disease.
A consortium of clinical researchers and trial experts have launched a new updated statement published by 39 researchers*, led by Professor Sally Hopewell, based in… Read More »New “CONSORT 2025 statement” has announced an expanded checklist to optimally conduct high-quality research on randomised trials.
LumiThera Inc., based in Seattle, Washington, USA, has recently received the U.S. Food & Drug Administration (FDA) authorisation, marketing for “Valeda Light Delivery System” for… Read More »LumiThera Inc., obtains FDA authorisation in the US on a photo-biomodulation (PBT) medical device – “Valeda” – for the treatment of dry AMD.
Dear EURETINA Members, A very warm welcome to the April 14th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »April 14th, 2025 “EURETINA-Brief”© Issue No. 314
Researchers at the Department of Genetics, and the Department of Ophthalmology, Harvard Medical School, Boston, have reported a novel gene-agnostic strategy treating retinitis pigmentosa (RP),… Read More »Novel research on a gene-agnostic strategy to treat RP aims to improve cone cell survival and extend vision.
Clinical researchers at the Sorbonne Université, INSERM, Institut de la Vision, Paris, have reported multiple pathogenic variants in the RP1L1 gene, associated with autosomal dominant,… Read More »Clinical analysis of phenotypic and genotypic characteristics on retinitis pigmentosa-1-like-1 (RP1L1) show associated retinopathy.
Atsena Therapeutics, based in Durham, North Carolina, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATSN-201, for… Read More »Atsena Therapeutics has announced the grant of U.S. FDA Fast Track Designation for ATSN-201 gene therapy for the treatment of X-linked retinoschisis.
Dear EURETINA Members, A very warm welcome to the March 31st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »March 31st, 2025 “EURETINA-Brief”© Issue No. 313
Researchers at the Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland, and the Centre for Medical Genetics, Ghent University, Belgium, have reported results of… Read More »A specific form of macular degeneration (MD) has uncovered three novel genetic variants encoding an adaptor protein (AP-5) complex, essential for macular function.
